Sacubitril - Wikipedia
Sacubitril - Wikipedia
VALSARTAN
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
sacubitril | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Sacubitril/Valsartan (LCZ696) | ARN Inhibitor | MedChemExpress
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Sacubitril - Wikipedia
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Bio <-> Chem: Back-story on Novartis LCZ696 database links
Frontiers | Neprilysin Inhibitors and Bradykinin
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
Bio <-> Chem: Back-story on Novartis LCZ696 database links
CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club
Sacubitril | New Drug Approvals
Sacubitril – Wikipedia
Sacubitril/valsartan - Wikipedia
Bio <-> Chem: Back-story on Novartis LCZ696 database links
PharmaWiki - Sacubitril
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. - Abstract - Europe PMC
Frontiers | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
SACUBITRIL
Heart failure with preserved ejection fraction: emerging drug strategies. - Abstract - Europe PMC
